

Joint working executive summary

<p>Project title</p>	<p><i>Joint Working Project between Sandwell and West Birmingham NHS Trust and Sanofi to improve identification and management of high-risk cardiovascular patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia in a primary care setting with associated triage of other high-risk groups to existing services.</i></p>
<p>Partner organisation/s</p>	<p><i>Sandwell and West Birmingham Hospitals NHS Trust</i></p> <p><i>Sanofi</i></p>
<p>Project rationale</p>	<p><i>The specific objectives of the project are:</i></p> <ul style="list-style-type: none"> <i>• Creation of a nurse led community lipid clinic within The Modality Group with clinical supervision provided by Consultant Chemical Pathologist at Sandwell and West Birmingham NHS Trust. *</i> <i>• Create and undertake a computer search which identifies high risk cardiovascular patients with elevated LDL-C to identify patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. *</i> <i>• Triage by Consultant Chemical Pathologist of the patients identified in order to direct them to the most appropriate clinic (Lipid, FH, Community Lipid or Cardiology) creating a clear integrated pathway for Primary Care. *</i> <i>• Proof of concept and reproducibility of a Community Lipid clinic.</i>
<p>Project period</p>	<p><i>Q4 2020 to Q4 2021</i></p>
<p>Project objectives</p>	<p><i>Patients</i></p> <ul style="list-style-type: none"> <i>• Increased diagnosis rate and improved management of high risk cardiovascular patients with elevated LDL-C.</i> <i>• Optimisation of treatment and lipid management</i> <i>• Improved access to specialised lipid service</i> <i>• Care closer to home</i> <i>• Patient empowerment and engagement in terms of their diagnosis and subsequent clinical management plan.</i> <p><i>The NHS:</i></p> <ul style="list-style-type: none"> <i>• Development of a primary care service that could be commissioned elsewhere/across other PCN's.</i> <i>• Increased capacity of lipid service</i> <i>• Reduction in waiting time.</i> <i>• Alignment with NHS Long term plan ⁽²⁾ and CVDPrevent Audit in Primary Care.</i>

	<ul style="list-style-type: none"> • Support implementation of NICE CG181⁽¹⁾ <p>Sanofi:</p> <ul style="list-style-type: none"> • The project aims to increase the diagnosis rate and improved management of high risk cardiovascular patients with elevated LDL-C - Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include Sanofi medicines for suitable patients in line with NICE TA393⁽³⁾ /TA394⁽⁴⁾ and or local / national guidelines • Demonstrates collaborative working and enhanced reputation with the NHS to the benefit of patients that identifies scalable solutions. <p>The NHS and Sanofi: An opportunity to document how joint working between Sandwell & West Birmingham Hospital Trust, Modality and Sanofi has improved the identification and management of patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. Potential scenarios for sharing best practice may include:</p> <ul style="list-style-type: none"> ○ Case Studies to share best practice with the NHS ○ Presentations to various NHS organisations ○ Conference abstracts, posters and presentations ○ Publications e.g. TBD
<p>Contact details</p>	<p>Professor Elizabeth Hughes - Consultant Chemical Pathologist and Deputy Medical Director- Sandwell & City Hospital Trust. Elizabeth.hughes@hee.nhs.uk</p> <p>Fleur Chandler- Director of Patient Access, UK & Ireland. 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. GB-MarketAccess@sanofi.com</p>